Human Bladder Cancer Tissue Lysates
Pricing |
Normal Lysates: $125.00/100 ug |
Tumor Lysates: $175.00/100 ug |
Nor./Tum. set: $270.00 (10% off) |
Discounts |
2-8 Vials 10% |
9-20 Vials 15% |
>20 Vials 20% |
Introduction:
Histologic types of urinary bladder cancer include the following:
More than 90% of bladder carcinomas are transitional cell carcinomas derived from the uroepithelium. About 6% to 8% are squamous cell carcinomas and 2% are adenocarcinomas. Adenocarcinomas may be either of urachal origin or of nonurachal origin; the latter type is generally thought to arise from metaplasia of chronically irritated transitional epithelium. Pathologic grade, which is based on cellular atypia, nuclear abnormalities, and the number of mitotic figures is of great prognostic importance.
Human Bladder Cancer Lysates | ||||||
Catalog Number |
Diagnosis |
Grade |
Stage |
TNM |
Sex |
Age |
Transitional cell carcinoma |
n/a |
I |
T1bNxM0 |
F |
57 |
|
Papillary transitional cell carcinoma |
1 |
II |
T2NxM0 |
M |
56 |
|
Transitional cell carcinoma |
2 |
II |
T2NxM0 |
M |
64 |
|
Epidermoid carcinoma |
2 |
III |
T3N0M0 |
M |
71 |
|
Papillary transitional cell carcinoma |
n/a |
n/a |
n/a |
M |
52 |
|
Transitional cell carcinoma |
1 |
II |
T2bN0M0 |
M |
42 |
|
Squamous cell carcinoma |
2 |
III |
T3NxM0 |
M |
39 |
|
Transitional cell carcinoma |
1 |
III |
T3NxM0 |
F |
45 |
|
Transitional cell carcinoma |
2 |
II |
T2bmN0M0 |
F |
52 |
|
Transitional cell carcinoma |
3 |
II |
T2bNxM0 |
M |
70 |
|
Squamous cell carcinoma |
3 |
II |
T2NxM0 |
M |
54 |
|
Squamous cell carcinoma |
2 |
II |
T2bNxM0 |
M |
62 |
|
Adenocarcinoma |
3 |
II |
T2mNxM0 |
M |
74 |
|
Transitional cell carcinoma |
2 |
II |
T2NxM0 |
M |
39 |
|
Transitional cell carcinoma |
n/a |
II |
T2bNxM0 |
M |
57 |
|
T10-016 | Transitional cell carcinoma, moderately differentiated. |
2 |
n/a |
n/a |
M |
74 |
Transitional cell carcinoma, moderately differentiated. |
2 |
n/a |
n/a |
F |
85 |
|
Transitional cell carcinoma, moderately differentiated. |
2 |
n/a |
n/a |
M |
76 |
|
Transitional cell carcinoma, poorly differentiated. |
3 |
n/a |
n/a |
M |
70 |
|
T10-020 | Transitional cell carcinoma, moderately differentiated. |
2 |
n/a |
n/a |
M |
39 |
T10-021 | Transitional cell carcinoma, moderately differentiated. |
2 |
n/a |
n/a |
M |
29 |
T10-022 | Transitional cell carcinoma, poorly differentiated. |
3 |
n/a |
T3bNxMx |
M |
70 |
T10-023 | Adenocarcinoma, moderately differentiated. |
2 |
n/a |
n/a |
M |
43 |
T10-024 | Transitional cell carcinoma, poorly differentiated. |
3 |
n/a |
n/a |
M |
62 |
Transitional cell carcinoma, poorly differentiated. |
3 |
n/a |
n/a |
M |
62 |
|
Transitional cell carcinoma, moderately differentiated. |
3 |
n/a |
n/a |
M |
63 |
|
Transitional cell carcinoma, poorly differentiated. |
3 |
n/a |
n/a |
M |
39 |
|
Transitional cell carcinoma, poorly differentiated. |
3 |
n/a |
n/a |
M |
75 |
|
Transitional cell carcinoma, well differentiated. |
1 |
n/a |
n/a |
M |
71 |
|
Adenocarcinoma, poorly differentiated. |
3 |
n/a |
n/a |
M |
67 |
References:
Mostofi FK, Davis CJ, Sesterhenn IA: Pathology of tumors of the urinary tract. In: Skinner DG, Lieskovsky G, eds.: Diagnosis and Management of Genitourinary Cancer. Philadelphia, Pa: WB Saunders, 1988., pp 83-117.
Wilson TG, Pritchett TR, Lieskovsky G, et al.: Primary adenocarcinoma of bladder. Urology 38 (3): 223-6, 1991.
LiVolsi VA: Pathology of thyroid disease. In: Falk SA: Thyroid Disease: Endocrinology, Surgery, Nuclear Medicine, and Radiotherapy. Philadelphia, PA: Lippincott-Raven, 1997., pp 127-175.